Clinical trial · Observational
Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice
ENDURANCE: Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Dutch Daily Clinical Practice. Part B1
NCT07663786CI-TRIAL-00115516active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study uses existing cancer registry and health record data to understand how nivolumab is used in routine care in the Netherlands for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Adenocarcinoma | Esophageal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastro-esophageal Junction Adenocarcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- Advanced/metastatic EAC/GEJAC/GAC participants
- description
- Participants diagnosed with HER2-negative unresectable advanced (cT4B) or synchronous metastatic (cM1) esophageal adenocarcinoma (EAC), gastro-esophageal junction adenocarcinoma (GEJAC), or gastric adenocarcinoma (GAC)
- label
- Cohort 2: Participants eligible for first-line nivolumab
- description
- Subset of Cohort 1 who are eligible for nivolumab treatment according to the European Medicines Association (EMA) approved indication
- label
- Cohort 3: Participants treated with first-line nivolumab
- description
- Subset of Cohort 2 who received nivolumab as part of first-line treatment
- interventionNames
- Drug: Nivolumab
Primary outcomes (1)
- measure
- Overall survival (OS) among participants treated with first-line nivolumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Registered in the Netherlands Cancer Registry (NCR) * Diagnosed with Esophageal Adenocarcinoma (EAC), Gastro-esophageal Junction Adenocarcinoma (GEJAC), or Gastric Adenocarcinoma (GAC) from 01-Aug-2022 to 31-Jul-2024 * Age ≥18 years at diagnosis * Unresectable advanced (cT4B) or synchronous metastatic (cM1) disease at diagnosis * (Cohort 2) Programmed cell Death Ligand 1 (PD-L1) CPS ≥5 * (Cohort 3) Received nivolumab as part of first-line treatment Exclusion Criteria: * Neuro-endocrine carcinomas or non-epithelial cancers of esophagus/ gastroesophageal junction /stomach * Positive HER2 expression
References
Publications (0)
Data not yet available
No reference posted for this study.